Endometriosis Market Size, Trends, Key Companies, Revenue Share Analysis, 2021-2028
Market Size – USD 2060.1 Million 2020, Market Growth – at a CAGR of 2.6%, Market Trends – Increased focus on improving women’s health
NEW YORK, NY, USA, April 20, 2022 /EINPresswire.com/ — The global endometriosis market is expected to reach USD 2,544.2 million in 2028 and register a stable revenue CAGR of 2.6% on the forecast period, according to the latest report published by Reports and Data. The key factors driving the revenue growth of the global market are the increased awareness for early diagnosis and treatment of endometriosis, as well as the high number of women of reproductive age who are exposed to the possibilities of contracting endometriosis.
Endometriosis is a chronic inflammatory disorder in which the endometrium, the tissue lining the uterus, grows outside the uterine cavity, causing irritation and lesion formation in the pelvis. Its common side effects include extreme pain during menstruation, pelvic pain, heavy bleeding, pain when urinating, painful bowel movements and intercourse. Factors such as the growing demand for advanced hormone therapies, improving healthcare systems and the availability of patient assistance programs designed by various major players to reduce the burden of treatment costs are some of the major drivers of market revenue growth. Other factors such as increased awareness of the importance of early detection and treatment of endometriosis and growing public and private sector efforts to raise awareness of the disease through marches, campaigns and educational programs are also driving the market revenue growth. In addition, factors such as the increasing focus on constant research and development, increased investment in the development of advanced therapeutic treatments, and increasing focus on the development of non-invasive diagnostic tests are expected to fuel the growth. market in the years to come.
However, unavailability of advanced therapies and treatment facilities in some developing economies, lack of non-invasive diagnostic techniques and high cost associated with advanced therapeutic drugs are key factors that might hamper the market growth in some measurement during the forecast period.
Get Sample Report @ https://www.reportsanddata.com/sample-enquiry-form/2553
Some highlights of the report:
On the basis of diagnostics, the Magnetic Resonance Imaging (MRI) segment is expected to register a rapid revenue CAGR between 2021 and 2028 due to the high prevalence of endometriosis globally, increasing need for diagnostic early detection, high efficiency and availability of technologically advanced MRI machines.
Among the drug type segments, the oral contraceptive pills segment is expected to witness the fastest revenue growth over the forecast period owing to easy availability, ability to reduce extreme pelvic pain, and large efficacy in preventing the recurrence of endometriotic lesions.
Among the treatment segments, the hormone therapy segment is expected to register a robust revenue CAGR during the forecast period. Factors such as the high utilization of various hormone therapies as first-line treatment, the easy availability of highly effective drugs, and the focus on developing improved hormone therapies to reduce pain during endometriosis are driving factors. segment revenue growth.
Among the end-use segments, the hospital segment is expected to register the highest revenue growth rate owing to the increase in hospital admissions and the availability of various over-the-counter and over-the-counter drugs. arrangement.
The endometriosis market in North America is expected to account for the largest revenue share during the forecast period. The high revenue share is attributed to factors such as increasing incidence of endometriosis, increasing reproductive population, and rapid advances in endometriosis therapies and treatments. Additionally, increasing number of drug approvals, emphasis on developing therapeutically advanced treatments, and presence of major market players are factors driving the North America market revenue growth.
The Asia-Pacific market is expected to register the fastest revenue CAGR during the forecast period owing to factors such as increasing prevalence of endometriosis in countries in the region, emphasis on the improving women’s health and raising women’s awareness of endometriosis and the importance of early diagnosis. Moreover, factors such as increasing healthcare expenditure and increasing investment in the development of new drugs and therapies are expected to drive the Asia-Pacific market revenue growth in the future.
AbbVie Inc., AstraZeneca Plc., Bayer HealthCare Pharmaceuticals, Debiopharm International SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Meditrina Pharmaceuticals Inc., Pfizer, Inc., Eli Lilly and Company, Abbott Laboratories, Neurocrine Biosciences, Inc., Astellas Pharma Inc., Evotec AG, Addex Therapeutics, Kissei Pharmaceutical Co., Ltd., ElexoPharm, EndoCeutics, Gedeon Richter Plc., Myovant Sciences, Mayne Pharma Group Ltd. and Merck and Co. Inc. are major companies profiled in the global market report.
In March 2020, Gedeon Richter Plc. has partnered with Myovant Sciences to market its relugolix combination tablet for endometriosis and uterine fibroids in Australia, Russia and New Zealand.
To know more about the report @ https://www.reportsanddata.com/report-detail/endometriosis-market
The report also offers detailed information on market segmentation based on type, application and regional bifurcation:
Endometriosis Market Segmentation:
Diagnostics Outlook (Revenue, USD Million; 2018-2028)
Magnetic Resonance Imaging (MRI)
Drug Type Outlook (Revenue, USD Million; 2018-2028)
Gonadotropins releasing hormone agonists
Oral contraceptive pills
Treatment Outlook (Revenue, USD Million; 2018-2028)
End-Use Outlook (Revenue, USD Million; 2018-2028)
Download Summary @ https://www.reportsanddata.com/download-summary-form/2553
The rest of Europe
Rest of APAC
Rest of LATAM
Middle East and Africa
United Arab Emirates
Rest of MEA
Request Report Customization @ https://www.reportsanddata.com/request-customization-form/2553
Thanks for reading the report. Please note that we also offer custom reports based on customer requirements. Contact us to know more about the personalization feature and our team will provide you with the best personalized report.
Browse more reports:
Biochip Market Size @ http://www.magazinestoday.co.nz/pr-newswire/?rkey=20220303IO80639&filter=5718
Biochip Market Share @ http://www.magazinestoday.co.nz/pr-newswire/?rkey=20220303EN80639&filter=5718
Biochip Market Size @ http://www.loupdargent.info/p/blog-page_24.html?rkey=20220303EN80639&filter=5206
Biochip Market Trends @ https://latinbusinesstoday.com/pr-newswire/?rkey=20220303IO80639&filter=11813
Biochip Market Trends @ https://www.commercialbiotechnology.com/index.php/jcb/biotechnology-news?rkey=20220303IO80639&filter=20231
Biochip Market Share @ http://www.interndaily.com/reports/prnewswire-interndaily-news.html?rkey=20220303IO80639&filter=1622
About reports and data
Reports and Data is a market research and consulting firm that provides syndicated research reports, custom research reports and consulting services. Our solutions are uniquely focused on your goal to locate, target and analyze changes in consumer behavior across demographics, across industries, and help customers make smarter business decisions. We offer market intelligence research ensuring relevant, fact-based research across multiple sectors including healthcare, touchpoints, chemicals, commodities and energy. We are constantly updating our search offerings to ensure that our clients are aware of the latest trends existing in the market. Reports and Data has a strong base of experienced analysts in various areas of expertise. Our industry experience and ability to develop a workable solution to any research problem gives our clients the ability to secure an edge over their respective competitors.
Reports and data
+ + 12127101370
write to us here
Visit us on social media: